
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. has demonstrated steady growth, with EsoGuard test volumes increasing by 2% year-over-year to 2,841 tests performed in 3Q25, exceeding prior estimates and showing positive sequential growth. The company is expected to experience significant revenue growth driven by expanding insurance coverage and increased engagement with Medicare, which represents approximately 50% of the addressable patient population. Furthermore, the positive outcome from the MolDX CAC meeting suggests a favorable coverage decision is on the horizon, enhancing Lucid's market positioning and potential upsides in its valuation.
Bears say
Lucid Diagnostics experienced a disappointing financial performance in the third quarter of 2025, missing consensus revenue expectations, which underlines concerns about market demand for its products, particularly EsoGuard. Additionally, despite maintaining stable operating expenses, the company incurred a pro forma net loss of $9.9 million, which indicates ongoing financial struggles and highlights potential liquidity risks in a challenging commercial environment. The decline in the number of EsoGuard tests processed compared to previous quarters further exacerbates the negative outlook, suggesting slower adoption and potential barriers to future revenue generation, compounded by risks associated with reimbursement and competition.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares